REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo shows promise for tough lymphoma cases
Disease control CompletedThis study tested a new drug (ociperlimab) combined with either tislelizumab or rituximab in 53 people whose diffuse large B-cell lymphoma had come back or stopped responding to treatment. The main goals were to check safety and find the best dose. Researchers also looked at whet…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 26, 2026 04:15 UTC
-
New drug cocktail shows promise for Tough-to-Treat lymphoma
Disease control CompletedThis early-phase trial tested a combination of two drugs, lenalidomide and blinatumomab, in 35 adults with non-Hodgkin lymphoma that returned or didn't respond to prior treatment. The main goal was to find the safest dose and identify side effects. Researchers also looked at whet…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 03:55 UTC
-
Can nivolumab rescue patients when CAR T-Cell therapy fails?
Disease control CompletedThis study tested the drug nivolumab in 20 people with blood cancers (like lymphoma, leukemia, or myeloma) that came back or didn't respond after CAR T-cell therapy. Nivolumab is an immunotherapy that helps the body's immune system attack cancer cells. The main goal was to see ho…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 03:54 UTC
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis early-phase study tested the safety and best dose of adding olaparib to high-dose chemotherapy for people with lymphomas that returned or didn't respond to treatment. 50 adults aged 18-65 took part. The goal was to see if this combination could work better before a stem cell…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
New hope for tough lymphoma: targeted pill shows promise in trial
Disease control CompletedThis study tested a drug called zanubrutinib in 65 adults with a hard-to-treat type of lymphoma (DLBCL) that has a specific gene change (CD79B mutation) and has come back or not responded to prior treatment. Participants took the drug as a pill and were monitored for tumor shrink…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated May 18, 2026 12:10 UTC
-
Can a booster shot for immune cells improve lymphoma treatment?
Disease control CompletedThis early-phase study tested a drug called NT-I7 (a long-acting immune booster) given after standard CAR-T cell therapy in 17 adults with large B-cell lymphoma that had come back or not responded to prior treatments. The main goal was to check safety and find the best dose. Rese…
Matched conditions: REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated May 07, 2026 18:42 UTC